<i>Campylobacter fetus</i> Invasive Infections and Risks for Death, France, 2000–2021

Zayet, Souheil; Klopfenstein, Timothée; Gendrin, Vincent; Vuillemenot, Jean-baptiste; Plantin, Julie; Toko, Lynda; Sreiri, Nour; Royer, Pierre-Yves

doi:10.3201/eid2911.230598

Cited by 4 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Infectious diseases are caused or transmitted by microorganisms such as bacteria, viruses, fungi, and parasites that can cause diseases in humans and animals 1 . These diseases can be transmitted through various modes, including contact with contaminated surfaces, ingestion of contaminated food or water, inhalation of airborne particles, or direct contact with infected individuals.…”

Section: Introductionmentioning

confidence: 99%

The importance, benefits, and future of nanobiosensors for infectious diseases

Dhahi,

Dafhalla,

Saad

et al. 2024

Biotech and App Biochem

View full text Add to dashboard Cite

Infectious diseases, caused by pathogenic microorganisms such as bacteria, viruses, parasites, or fungi, are crucial for efficient disease management, reducing morbidity and mortality rates and controlling disease spread. Traditional laboratory‐based diagnostic methods face challenges such as high costs, time consumption, and a lack of trained personnel in resource‐poor settings. Diagnostic biosensors have gained momentum as a potential solution, offering advantages such as low cost, high sensitivity, ease of use, and portability. Nanobiosensors are a promising tool for detecting and diagnosing infectious diseases such as coronavirus disease, human immunodeficiency virus, and hepatitis. These sensors use nanostructured carbon nanotubes, graphene, and nanoparticles to detect specific biomarkers or pathogens. They operate through mechanisms like the lateral flow test platform, where a sample containing the biomarker or pathogen is applied to a test strip. If present, the sample binds to specific recognition probes on the strip, indicating a positive result. This binding event is visualized through a colored line. This review discusses the importance, benefits, and potential of nanobiosensors in detecting infectious diseases.

show abstract

Section: Introductionmentioning

confidence: 99%

The importance, benefits, and future of nanobiosensors for infectious diseases

Dhahi,

Dafhalla,

Saad

et al. 2024

Biotech and App Biochem

View full text Add to dashboard Cite

show abstract

“…In our paper, we have highlighted an outbreak of M. pneumoniae infection in Nord Franche-Comté Hospital, a French district general hospital with a capacity of 1,216 beds and about 100,000 visits to its emergency rooms per year [ 4 ], so as to alert the medical community about a possible emergence of this pathogen and what appears to be its changing attributes. Our patients reside in Franche-Comté (Belfort-Montbeliard), a region of about 300,000 habitants in the East of France, close to the Swiss and German borders.…”

mentioning

confidence: 99%

Outbreak of Mycoplasma pneumoniae pneumonia in hospitalized patients: Who is concerned? Nord Franche-Comté Hospital, France, 2023–2024

Zayet,

Poloni,

Plantin

et al. 2024

Epidemiol. Infect.

Self Cite

View full text Add to dashboard Cite

We report an outbreak of confirmed Mycoplasma pneumoniae community-acquired pneumonia (CAP) in Nord Franche-Comté Hospital, France, from 14 November 2023 to 31 January 2024. All 13 inpatients (11 adults with a mean age of 45.5 years and 2 children) were diagnosed with positive serology and/or positive reverse transcription polymerase chain reaction (RT-PCR) on respiratory specimens. All patients were immunocompetent and required oxygen support with a mean duration of oxygen support of 6.2 days. Two patients were transferred to the intensive care unit (ICU) but were not mechanically ventilated. Patients were treated with macrolides (n = 12, 92.3%) with recovery in all cases. No significant epidemiological link was reported in these patients.Global prospective surveillance data suggest a recent re-emergence of Mycoplasma pneumoniae (M. pneumonia) infection in Europe and Asia. This delayed re-emergence is striking because it occurred sometime after non-pharmaceutical interventions against COVID-19 were discontinued, and a possible circulation of M. pneumoniae is usually described as endemic, punctuated with cyclic epidemics every 3 to 5 years [1]. M. pneumoniae beyond the COVID-19 pandemic surveillance is needed [2,3].In our paper, we have highlighted an outbreak of M. pneumoniae infection in Nord Franche-Comté Hospital, a French district general hospital with a capacity of 1,216 beds and about 100,000 visits to its emergency rooms per year [4], so as to alert the medical community about a possible emergence of this pathogen and what appears to be its changing attributes. Our patients reside in Franche-Comté (Belfort-Montbeliard), a region of about 300,000 habitants in the East of France, close to the Swiss and German borders. In the period from 14 November 2022 to 31 January 2023 (the same period in the previous year), only one patient (a 15-year-old man) was diagnosed in our hospital for M. pneumoniae-associated community-acquired pneumonia (CAP) (Figure 1). Our series consisted of 13 confirmed cases of M. pneumoniae CAP (11 adults and 2 older children) in hospitalized patients in Nord Franche-Comté Hospital between 14 November 2023 and 31 January 2024. In adult inpatients, the mean age was 45.5 years (range: 19-70) with a male predominance (72.7%). All patients were considered as immunocompetent mostly without comorbidities (Charlson comorbidity index mean at 0.5 (range: 0-2)). Tobacco consumption was noted in 45.5% of adult patients (n = 5). The 13 patients had no direct contact with each other, and no significant epidemiological links were discovered. Two adult patients reported similar respiratory presentations in their children. M. pneumoniae was a part of a polymicrobial infection in only one patient, and a second one had co-infection with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (paucisymptomatic form with no respiratory symptoms initially). Diagnosis in all patients was based on positive serology (IgM and IgG) and/or positive specific or multiplex reverse transcription polymer...

show abstract